Multiple Sclerosis Clinical Trial
Official title:
Feasibility and Initial Efficacy of a Wheelchair Exercise-training Intervention for Persons With Multiple Sclerosis
The goal of this randomized controlled clinical trial is to examine the feasibility and initial efficacy of undertaking and delivering a novel, stakeholder-informed exercise training program for wheelchair users with multiple sclerosis. The main questions it aims to answer are: - Is the study feasible as measured by participant recruitment (24 participants total), retention (80%), and safety (adverse events)? - Is the study acceptable as measured by participant satisfaction and perceptions using an evaluation survey and semi-structured interviews? - Is there significant change in following the 16-week study in metabolic health outcomes, MS symptoms, and exercise behavior change? Participants will be randomized to complete the 16-week SPIN exercise training program or WellMS attention/contact wellness program. Researchers will compare the SPIN and WellMS groups to determine if there is a significant difference in metabolic health outcomes, MS symptoms, and exercise behavior change.
Status | Recruiting |
Enrollment | 24 |
Est. completion date | October 31, 2024 |
Est. primary completion date | October 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - diagnosis of MS - self-reported use of a wheelchair (i.e., manual wheelchair, power wheelchair, or scooter) >50% of the time - age of 18 years or older - relapse free for the past 30 days - being non-active defined as not engaging in regular physical activity (30 minutes accumulated per day) on more than 2 days of the week during the previous 6 months (i.e., not meeting current physical activity guidelines for MS) Exclusion Criteria: - during telephone screening participants will complete an exercise pre-participation health screen and if participants report any symptoms or conditions contradictive of exercise then physician clearance will be required before enrollment |
Country | Name | City | State |
---|---|---|---|
United States | The University of Texas Health Science Center at Houston | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
The University of Texas Health Science Center, Houston | Craig Hospital, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), University of Illinois at Chicago |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change of Physical Activity levels through the Godin Leisure-Time Exercise Questionnaire | Physical activity will be assessed using the Godin Leisure-Time Exercise Questionnaire. Total Godin Leisure Time Exercise Questionnaire scores range from 0-119, with higher scores indicating more exercise behavior. Participants will complete this questionnaire at baseline and 16 weeks. | 16-weeks | |
Other | Change in Metabolic Health Outcomes: Triglycerides | Triglycerides will be measured in partnership with Quest Diagnostics using the standard Diabetes Risk without Score panel at a location convenient to participants within their community. Participants will complete blood sample collection at baseline and 16 weeks. | 16-weeks | |
Other | Change in Metabolic Health Outcomes: HbA1c | HbA1c will be measured in partnership with Quest Diagnostics using the standard Diabetes Risk without Score panel at a location convenient to participants within their community. Participants will complete blood sample collection at baseline and 16 weeks. | 16-weeks | |
Other | Change in Metabolic Health Outcomes: Cholesterol | Cholesterol levels will be measured in partnership with Quest Diagnostics using the standard Diabetes Risk without Score panel at a location convenient to participants within their community. Participants will complete blood sample collection at baseline and 16 weeks. | 16-weeks | |
Other | Change in Metabolic Health Outcomes: Glucose | Fasting glucose will be measured in partnership with Quest Diagnostics using the standard Diabetes Risk without Score panel at a location convenient to participants within their community. Participants will complete blood sample collection at baseline and 16 weeks. | 16-weeks | |
Other | Adherence to assigned condition | We will ask all participants to complete a weekly form in an individual REDCap portal with the information from their logbook as an additional measure of adherence to the exercise training or wellness program (i.e., behavior change). | 16-weeks | |
Other | Change in MS Symptoms: Fatigue | Fatigue will be assessed using the Fatigue Severity Scale. Fatigue Severity Scale scores range from 9-63, with higher scores indicating greater fatigue. Participants will complete this questionnaire at baseline and 16 weeks. | 16-weeks | |
Other | Change in MS Symptoms: Pain | Pain will be assessed using the McGill Pain Questionnaire-Short Form. McGill Pain Questionnaire-Short Form scores range from 0-45, with higher scores indicating greater pain. Participants will complete this questionnaire at baseline and 16 weeks. | 16-weeks | |
Other | Change in MS Symptoms: Depression | Depressive symptoms will be assessed using the Hospital Anxiety and Depression Scale. Hospital Anxiety and Depression Scale depression subscale scores range from 0-21, with higher scores indicating greater depressive symptoms. Participants will complete this questionnaire at baseline and 16 weeks. | 16-weeks | |
Other | Change in MS Symptoms: Quality of life | Quality of life will be assessed using the 12-item Short Form Survey. The 12-item Short Form Survey scores include mental and physical component subscale scores, which each range from 0-100, with higher scores indicating greater quality of life. Participants will complete this questionnaire at baseline and 16 weeks. | 16-weeks | |
Other | Change of Physical Activity levels through Accelerometery from baseline at 16 weeks | Physical activity will be assessed using an ActiGraph accelerometer. Participants will wear an accelerometer on a wristband on their nondominant wrist during the waking hours of a 7 day period. Participants will complete this at baseline and 16 weeks. | 16-weeks | |
Primary | Study Feasibility: Number of Participants Recruited | Feasibility of the intervention will be measured based on reaching recruitment goals (n=24) within a one-year period. All contacts between interested participants will be recorded in a REDCap database to assess recruitment. | 16-weeks | |
Primary | Study Feasibility: Number of Participants Retained | Feasibility of the intervention will be measured based on retention of >80% of enrolled participants for the full 16-week study period. All contacts between enrolled participants will be recorded in a REDCap database to assess retention. | 16-weeks | |
Primary | Study Feasibility: Incidence of Adverse Events | Feasibility of the intervention will be measured in terms of <10% of participants reporting adverse events. All contacts between enrolled participants will be recorded in a REDCap database to assess retention. | 16-weeks | |
Secondary | Acceptability: Semi-structured interview | Acceptability of the intervention will be determined using semi-structured interviews. All participants will be invited to complete a post-test semi-structured interview online via Zoom with the graduate research assistant that will last 20-40 minutes. A standard interview guide will be used to provide a rich assessment of acceptability and suggestions for refining the exercise training program. | 16-weeks | |
Secondary | Acceptability: Survey | Acceptability of the intervention will be determined using a post-test evaluation survey. Survey items will include Likert ratings of participant satisfaction with the program and utility of all condition-specific components (e.g., equipment and coaching) plus include open-ended questions where participants can report their preferred components and offer suggestions for improvement. | 16-weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |